Patents by Inventor Guochuang ZHENG

Guochuang ZHENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF
    Publication number: 20240116918
    Abstract: The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (A) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a preparation method therefor, a pharmaceutical composition containing the compounds, and the use of the compounds or the composition for treating a disease mediated by PRMT5. The compounds of the present invention show significant inhibitory activity on PRMT5.
    Type: Application
    Filed: October 12, 2020
    Publication date: April 11, 2024
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Xu Quan, Guochuang Zheng, Wei Sun, Tingting Yang, Kangning Zhan, Qiqi Shi
  • Compound as ACC inhibitor and use thereof
    Patent number: 11186587
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 30, 2021
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Yazhou Wang, Xu Quan, Chunhuan Jiang, Hongyan Chen, Menghua Chen, Chao Li, Yexin Liao, Qi Liu, Chen Wang, Hai Wang, Shengwei Yang, Guochuang Zheng
  • COMPOUND AS ACC INHIBITOR AND USE THEREOF
    Publication number: 20200165265
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Application
    Filed: July 25, 2018
    Publication date: May 28, 2020
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong WANG, Liwen ZHAO, Yazhou WANG, Xu QUAN, Chunhuan JIANG, Hongyan CHEN, Menghua CHEN, Chao LI, Yexin LIAO, Qi LIU, Chen WANG, Hai WANG, Shengwei YANG, Guochuang ZHENG